Abstract
Molecular characterization of high-grade glioma (HGG) at recurrence is promising for disease monitoring and therapeutic decision. We aimed to analyze the mutational profile between primary tumor and circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) obtained at recurrence in patients treated for a HGG.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
